Harrow Health Inc (HROW)vsNovartis AG ADR (NVS)
HROW
Harrow Health Inc
$33.07
-0.09%
HEALTHCARE · Cap: $1.41B
NVS
Novartis AG ADR
$145.46
+1.32%
HEALTHCARE · Cap: $271.25B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 20471% more annual revenue ($56.69B vs $275.59M). NVS leads profitability with a 22.5% profit margin vs -13.5%. NVS earns a higher WallStSmart Score of 51/100 (C-).
HROW
Avoid23
out of 100
Grade: F
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for HROW.
Margin of Safety
-53.7%
Fair Value
$93.40
Current Price
$145.46
$52.06 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Areas to Watch
Smaller company, higher risk/reward
Trading at 80.7x book value
ROE of -35.4% — below average capital efficiency
Earnings declined 10.3%
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : HROW
Revenue growth of 10.9% demonstrates continued momentum.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bear Case : HROW
The primary concerns for HROW are Market Cap, Price/Book, Return on Equity. Debt-to-equity of 19.79 is elevated, increasing financial risk.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Key Dynamics to Monitor
HROW profiles as a turnaround stock while NVS is a value play — different risk/reward profiles.
NVS carries more volatility with a beta of 0.49 — expect wider price swings.
HROW is growing revenue faster at 10.9% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 23/100), backed by strong 22.5% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Harrow Health Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Harrow Health, Inc. is an ophthalmology-focused healthcare company. The company is headquartered in San Diego, California.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?